semaglutide bs tirzepatide Subcutaneously administered vs for adults with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials | Diabetologia Semaglutide vs. Tirzepatide for Weight

Earlier Phase 2 data corroborated these findings, showing that up to 82% of participants achieved a target HbA1c of less than 6.5%

It's not about one being definitively 'better' than the other

Many experience an additional 5 to 10 percent body weight loss after switching, though the timeline for this additional loss varies

A finding that appears compound-related may come from concentration, injection technique, repeated site use, or an observation window that misses the expected pulse-like behavior of the peptide

Many patients prescribed Ozempic or similar GLP-1 receptor agonist drugs to treat diabetes or support weight management have reported severe and prolonged vomiting, stomach paralysis, intestinal obstruction, and other serious gastrointestinal injuries

Semaglutide is a breakthrough in the battle against overweightness and obesity